alpha-glucosidase Inhibitors
1 drugsAbout alpha-glucosidase
Alpha-glucosidase, located in the small intestine, breaks down complex carbohydrates into glucose. This enzyme plays a key role in carbohydrate metabolism and postprandial glucose levels.
Inhibiting alpha-glucosidase is a therapeutic strategy for managing type 2 diabetes by reducing postprandial hyperglycemia. Currently, there is no genetic evidence directly linking alpha-glucosidase to specific diseases.
Miglitol is the only FDA-approved drug targeting alpha-glucosidase, available as a small molecule. Westminster Pharmaceuticals is the sole company with an approved alpha-glucosidase inhibitor.
Strategic Insights
ℹ️ How we calculate- Less competitive landscape offers potential first-mover advantages.
- White space opportunity in Healthy with only 1 trials.
Top Drugs
Westminster Pharmaceuticals is the only company with an approved drug.
The lack of competition suggests high barriers to entry or limited market potential.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha-glucosidase, using small molecule modality.
Exploring alternative modalities could provide a competitive advantage in this space.
Clinical Trials 5 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2015 - 2015)
The first and only drug, Miglitol, was approved in 2015.
The stagnant approval timeline indicates a potentially saturated market or lack of innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Low (3 sponsors)
- • White space: 8 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 3 clinical trials targeting alpha-glucosidase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities